Aducanumab Approved for Treatment of Alzheimer's Disease

Aducanumab Approved for Treatment of Alzheimer's Disease

FDA approval of aducanumab for treatment of Alzheimer's 

Aducanumab has been approved as a treatment for Alzheimer's by the U.S. Food and Drug Administration (FDA). Aducanumab is the first FDA- approved therapy to potentially delay decline from the disease, compared to current medications that only address symtoms. 

It is also the first therapy to demonstrate that removing amyloid from the brain may delay decline in people living with Alzheimer's. Approval of this therapy underscores the importance of early detection and diagnosis to ensure individuals recieve the most venefit as soon as possible. 

Aducanumab is not a cure but is a very important advance for treatment. The therapy has not yet been tested on people with more advacned cases of dementia. 

To receive Aducanumab from a physician, individuals must undergo an FDA-required diagnostic test. 

The historic approval of Aducanumab ushers in an exciting era in Alzheimer's and demnetia treatment and research. Approvals of the first drug in a new category benefit peole living with the disease by invigorating the field, increasing investments in treatments and generating innovation. 


Leave a Comment:

Your email address will not be published. Required fields are marked *

Find a nearby center